Publication of Annual Report and Notice of AGM

March 31st, 2023


(“BiVictriX” or the “Company”)

Publication of Annual Report and Notice of AGM

Alderley Park, 31st March 2023 – BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next-generation cancer therapies with improved tolerability and anti-cancer activity, announces that its annual report and financial statements for the year ended 31 December 2022 (“Annual Report and Accounts”) are now available for download on the Company’s website at; and confirms the date for its Annual General Meeting (“AGM”).

Copies of the Annual Report and Accounts and the Notice of AGM will also be mailed to shareholders, who have elected to opt out on receiving electronic communications, later today.

The Company will hold its AGM on 4th May 2023 at 11.30 am BST at the Company’s registered office, Mereside Alderley Park, Alderley Edge, Manchester, SK10 4TG.


 For more information, please contact:

BiVictriX Therapeutics plc
Tiffany Thorn, Chief Executive Officer
Michael Kauffman, Non-Executive Chairman

SP Angel Corporate Finance LLP (NOMAD and Broker)
David Hignell, Kasia Brzozowska (Corporate Finance
Vadim Alexandre, Rob Rees (Sales and Broking)

Tel: +44 (0) 20 3470 0470

Panmure Gordon (UK) Limited (Joint Broker)
Rupert Dearden/Freddy Crossley/Emma Earl

Tel: +44 (0) 20 7886 2500

Consilium Strategic Communications
Mary-Jane Elliott, Namrata Taak,
Genevieve Wilson, Emmalee Hoppe
Tel: +44 (0) 20 3709 5700


About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a new class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst significantly reducing treatment-related toxicities.

The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni® Antibody Drug Conjugate therapeutics which are designed to selectively target cancer-specific antigen pairs, or “Bi-Cygni® fingerprints”, on tumour cells, which are largely absent from healthy cells.

BiVictriX has established a growing proprietary library of cancer-specific Bi-Cygni® fingerprints, which enable the Company to target a diverse array of different cancer types. The Company utilises these novel Bi-Cygni® fingerprints, together with the Company’s novel Antibody Drug Conjugate therapeutic design, to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and areas of high unmet medical need.

Find out more about BiVictriX online at